The Latest Cardiac and Vascular News
Statistically Significant Reduction in CV Mortality and HF Rehospitalizations as Compared to IV Diuretics at 30 and 90 Days MINNEAPOLIS, Oct. 03, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the results of the AVOID-HF […]
REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overload MINNEAPOLIS, Sept. 27, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the activation of three additional sites […]
Data show ultrafiltration for post-operative CABG patients provides a safe and effective method for managing fluid balance and reducing mortality rates MINNEAPOLIS, Aug. 31, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the publication of key clinical […]
MINNEAPOLIS, Aug. 09, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the second quarter ended June 30, 2022, which included the following highlights: Generated $2.2 million in total revenue for the second quarter 2022, up 15% sequentially from the first quarter of 2022, Enrolled first […]
The Finkelstein-Schoenfeld Method of Win Ratios Analysis Provides New Insights Into Superiority of Ultrafiltration over Diuretics in Treating Fluid Overloaded Heart Failure Patients Resistant to Diuretics MINNEAPOLIS, July 26, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) a commercial-stage company focused on improving the quality of life for people with fluid overload, […]
MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on improving the quality of life for people with fluid overload, today announced key takeaways from its recent physician-led webinar discussing the benefits of treating fluid overloaded heart failure (HF) patients with Aquadex® ultrafiltration (UF) in the […]
REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overload MINNEAPOLIS, June 29, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) today announced the first patient has been enrolled in the company’s pivotal REVERSE-HF (Ultrafiltration Versus IV Diuretics in Worsening Heart Failure) clinical study. REVERSE-HF will evaluate […]
Pediatric Segment Growth Continues at 36% CAGR MINNEAPOLIS, June 14, 2022 (GLOBE NEWSWIRE) — Improving access to life-saving fluid management therapies is a commitment by which Nuwellis, Inc. (Nasdaq: NUWE) stands. The company today announced its Aquadex SmartFlow® system is now available at two new pediatric hospitals in Florida and Arkansas. “By […]
The REVERSE-HF study will evaluate ultrafiltration therapy for heart failure patients suffering from fluid overload MINNEAPOLIS, March 15, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) today announced it has received independent Institutional Review Board (IRB) approval for the trial protocol of the company’s REVERSE-HF (Ultrafiltration Versus IV Diuretics in Worsening Heart Failure) clinical study […]
MINNEAPOLIS, March 01, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the fourth quarter and full year ended December 31, 2021, which included the following highlights: Generated $1.6 million in total revenue for the fourth quarter 2021, 19.6% below the prior-year period and a 20% […]
